Evaluate the Efficacy and Safety of Pasireotide LAR on the Treatment of Patients With Clinically Non-Functioning Pituitary Adenoma. (Passion I)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years and older (Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Non-functioning pituitary adenoma ≥ 1cm, patients without any previous treatment for the tumor
Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
Patients who require a surgical intervention for relief of any sign or symptom associated with tumor compression
Previous pituitary surgery
Previous medical treatment for pituitary tumor
Patients who have received pituitary irradiation within 10 years prior to randomization
Prolactin (PRL) levels > 100 ng/mL. PRL evaluation should be performed with diluted samples to make sure to avoid the "hook effect."
Patients presenting prolactinomas, acromegaly or Cushing's disease
Patients with compression of the optic chiasm causing acute clinically significant visual field defects
Other protocol-defined inclusion/exclusion criteria may apply
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Central Nervous System Diseases
Nervous System Diseases
Endocrine System Diseases
Endocrine Gland Neoplasms
Neoplasms by Site
Central Nervous System Neoplasms
Nervous System Neoplasms
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs